1. Home
  2. AEVA vs ANL Comparison

AEVA vs ANL Comparison

Compare AEVA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeva Technologies Inc.

AEVA

Aeva Technologies Inc.

HOLD

Current Price

$10.20

Market Cap

1.1B

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.58

Market Cap

998.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEVA
ANL
Founded
2019
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
998.8M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
AEVA
ANL
Price
$10.20
$10.58
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$29.00
★ $29.50
AVG Volume (30 Days)
★ 1.4M
308.7K
Earning Date
11-04-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 10.53
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$78.97
$243.83
Revenue Next Year
$124.76
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.83
$0.88
52 Week High
$31.30
$17.25

Technical Indicators

Market Signals
Indicator
AEVA
ANL
Relative Strength Index (RSI) 29.81 35.97
Support Level N/A $8.96
Resistance Level $16.49 $12.49
Average True Range (ATR) 0.76 1.37
MACD -0.16 -0.35
Stochastic Oscillator 12.48 5.05

Price Performance

Historical Comparison
AEVA
ANL

About AEVA Aeva Technologies Inc.

Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: